GlyTech is a science-driven biotechnology company focusing on bringing glycans, which have been called the third chain of life, into practical therapeutic use. Our unparalleled platform technologies of human-type glycan production and glycosylation allow access to highly pure and structurally controlled glycans for drug modification. Our ability to precisely attach desired glycans to a broad range of drug types allows us to support our partners in a wide variety of drug development areas from basic research to manufacturing. A high level of control enables glycosylation patterns (structure, number, position) to be optimized to exploit potential benefits which include increased biological activity, prolonged half-life, and enhanced solubility. Our methods can help our partners　advance discovery targets toward the clinic and develop new biotherapeutics more efficiently. We’ve also overcome one of the greatest barriers to the use of glycans in medicines: limited production capabilities. Our unique platforms allow us to produce both single glycan structures and uniformly glycosylated compounds on a practical and cost-effective scale from the research laboratory to commercialization. We are committed to helping our partners expand their glycoscience research fields, drug development options, and biotherapeutic analysis capabilities. We believe that technology, partnership, and passion are the 3 key success factors in the healthcare industry. With strong experience and an eagerness to tackle new challenges, we are ready to help our partners explore the possibilities of applied glycoscience. We invite you to get our updates by following us on Twitter or here on LinkedIn, or contact us through our homepage: https://www.glytech-inc.com/contact-us/